Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 2 - What They Never Told You

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

StockNews.com

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

StockNews.com

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

StockNews.com

2 Biotech Stock to Buy Over Moderna This December

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

StockNews.com

3 Biotech Stocks to Help You Build a Healthy Portfolio

Biotech industry played a vital role amid the pandemic and continues to witness solid demand amid rising medical needs and chronic diseases. Investor sentiment toward biotech stocks is robust. As biotech is considered a defensive sector against market downturns, investors might buy quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB),…

StockNews.com

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

Benzinga

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

Are Pot Stocks Back in Play? 3 Names to Consider

Legalization and growing medicinal benefits are driving the cannabis market’s growth. With disruptive long-term prospects in sight, we think pot stocks, Constellation Brands (STZ), Altria Group (MO), and Jazz Pharmaceuticals (JAZZ) could be solid additions to one’s portfolio now. Read on….

StockNews.com

2 Biotech Stocks Crushing It During the Market Crash

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

StockNews.com

Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced topline results from the Phase 3 RELEASE MSS1 trial of nabiximols oromucosal spray on clinical measures of spasticity in multiple sclerosis. The trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21. Nabiximols oromucosal spray is a complex…

Benzinga

Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired development and commercialization rights in the U.S., Europe, and other territories for Sumitomo Pharma's investigational DSP-0187. DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist with potential application for treating narcolepsy, idiopathic hypersomnia, and other sleep disorders. Jazz has designated this molecule JZP441. Sumitomo Pharma initiated a Phase…

Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Benzinga

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ:HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule. "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating…

Benzinga

Jazz Pharma Building New State-Of-The-Art Facility For Cannabis-Based Research And Production

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.

Benzinga

Jazz Pharma Getting New State-Of-The-Art Facility For Cannabis-Based Research And Production

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022.

1 2

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.